Vision & mission

THE CURRENT ONCOLOGY SCENARIO ESTIMATES THAT IN ITALY, DURING THE COURSE OF THE LIFE, IN AVERAGE, ONE MAN OUT OF 2 AND A WOMAN OUT OF 3 WILL DEVELOP TUMOR.

This probability is distributed over the course of life.

Age ranges Men Women
Between 0 and 49 years old 1 out of 28 1 out of 17
Between 50 and 69 years old 1 out of 5 1 out of 7
Between 50 and 69 years old 1 out of 3 1 out of 5

CONSIDERING THE ENTIRE POPULATION, AND EXCLUDING SKIN CARCINOMAS, THE MOST FREQUENT TUMOR FORMS ARE:

BREAST

COLORECTAL

LUNG

PROSTATE

DESPITE THE HIGH CHANCE TO DEVELOP TUMOR DURING LIFE, THE MORTALITY IS DECREASING IN BOTH SEXES, IN FACT, THE PROJECTION TO 2016 OF THE NUMBER OF PEOPLE LIVING IN ITALY AFTER A TUMORAL DIAGNOSIS IS MORE THAN 3,1 MILLIONS (3.136.709), 1,4 MILLIONS MALES AND 1,7 FEMALES (3.036.741, 2015 DATA)

Data Source Airtum 2016

Genoma Group with OnconextTMopeningTM, the genetics and molecular biology division dedicated to oncology, wants to help improve diagnosis and to perfect prognosis in order to concretely increase the quality and the expectations of life of oncology patients, or at high risk to become one.

Innovation, technology and expertise allowed the opening of the OnconextTM divisionTM, and Genoma Group’s commitment is dedicated to the oncology world with a double goal: to help the professional providing the most innovative and spot on instruments, while at the same time ensuring the respect of the patient and his right to be treated in a personalised way.